SMAD4 and pulmonary arterial hypertension: One- and three-year survival rates were individually 78% and 53% for HHT-PAH patients, suggestively lower than patients with IPAH one- and three-year survival rates at 91% and 74% individually [56]. SMAD4 in the pathogenesis of HPAH is not completely known.